Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.16 Billion INR | -24.5% |
| 2022 | 5.72 Billion INR | 177.76% |
| 2021 | 2.06 Billion INR | 0.34% |
| 2020 | 2.05 Billion INR | 13.27% |
| 2019 | 1.81 Billion INR | 26.98% |
| 2018 | 1.42 Billion INR | 7.12% |
| 2017 | 1.33 Billion INR | 7.52% |
| 2016 | 1.23 Billion INR | 16.65% |
| 2015 | 1.06 Billion INR | 10.52% |
| 2014 | 961.34 Million INR | 7.03% |
| 2013 | 898.18 Million INR | 14.93% |
| 2012 | 781.5 Million INR | 16.89% |
| 2011 | 668.54 Million INR | 55.66% |
| 2010 | 429.5 Million INR | 10.74% |
| 2009 | 387.83 Million INR | 23.69% |
| 2008 | 313.56 Million INR | 20.22% |
| 2007 | 260.81 Million INR | -1.77% |
| 2006 | 265.51 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion INR | 6.33% |
| 2024 Q1 | 1.04 Billion INR | -6.36% |
| 2023 Q4 | 1.11 Billion INR | -22.36% |
| 2023 Q2 | 1.48 Billion INR | 3.75% |
| 2023 FY | 4.32 Billion INR | -24.5% |
| 2023 Q1 | 1.43 Billion INR | -1.75% |
| 2023 Q3 | 1.43 Billion INR | -3.66% |
| 2022 FY | 5.72 Billion INR | 177.76% |
| 2022 Q4 | 1.45 Billion INR | 1.98% |
| 2022 Q2 | 1.44 Billion INR | 4.74% |
| 2022 Q1 | 1.38 Billion INR | 180.85% |
| 2022 Q3 | 1.43 Billion INR | -1.36% |
| 2021 FY | 2.06 Billion INR | 0.34% |
| 2021 Q4 | -1.71 Billion INR | -224.09% |
| 2021 Q3 | 1.37 Billion INR | 12.29% |
| 2021 Q1 | 1.16 Billion INR | 191.16% |
| 2021 Q2 | 1.22 Billion INR | 5.56% |
| 2020 Q4 | -1.27 Billion INR | -212.62% |
| 2020 Q1 | 1.03 Billion INR | 182.74% |
| 2020 Q2 | 1.16 Billion INR | 12.08% |
| 2020 Q3 | 1.13 Billion INR | -2.31% |
| 2020 FY | 2.05 Billion INR | 13.27% |
| 2019 Q3 | 1.08 Billion INR | 3.13% |
| 2019 Q4 | -1.25 Billion INR | -215.72% |
| 2019 FY | 1.81 Billion INR | 26.98% |
| 2019 Q2 | 1.04 Billion INR | 12.29% |
| 2019 Q1 | 933.9 Million INR | 192.58% |
| 2018 FY | 1.42 Billion INR | 7.12% |
| 2018 Q3 | 862 Million INR | 8.71% |
| 2018 Q1 | 781.3 Million INR | 0.57% |
| 2018 Q4 | -1 Billion INR | -217.02% |
| 2018 Q2 | 792.9 Million INR | 1.48% |
| 2017 FY | 1.33 Billion INR | 7.52% |
| 2017 Q4 | 776.9 Million INR | -1.46% |
| 2017 Q3 | 788.4 Million INR | 4.52% |
| 2017 Q2 | 754.3 Million INR | 7.05% |
| 2017 Q1 | 704.6 Million INR | 2.26% |
| 2016 Q1 | 616.5 Million INR | 1.63% |
| 2016 Q4 | 689 Million INR | 4.28% |
| 2016 FY | 1.23 Billion INR | 16.65% |
| 2016 Q2 | 669 Million INR | 8.52% |
| 2016 Q3 | 660.7 Million INR | -1.24% |
| 2015 Q2 | 563.6 Million INR | 4.84% |
| 2015 Q4 | 606.6 Million INR | 7.71% |
| 2015 Q3 | 563.2 Million INR | -0.07% |
| 2015 Q1 | 537.6 Million INR | 198.02% |
| 2015 FY | 1.06 Billion INR | 10.52% |
| 2014 Q2 | 516.1 Million INR | 6.11% |
| 2014 Q4 | -548.45 Million INR | -208.07% |
| 2014 FY | 961.34 Million INR | 7.03% |
| 2014 Q3 | 507.5 Million INR | -1.67% |
| 2014 Q1 | 486.4 Million INR | 195.9% |
| 2013 Q2 | 480.8 Million INR | 8.43% |
| 2013 Q3 | 481.2 Million INR | 0.08% |
| 2013 Q4 | -507.21 Million INR | -205.41% |
| 2013 FY | 898.18 Million INR | 14.93% |
| 2013 Q1 | 443.4 Million INR | 14.54% |
| 2012 FY | 781.5 Million INR | 16.89% |
| 2012 Q1 | 127.8 Million INR | 0.0% |
| 2012 Q2 | 130.1 Million INR | 1.8% |
| 2012 Q3 | 136.3 Million INR | 4.77% |
| 2012 Q4 | 387.1 Million INR | 184.01% |
| 2011 FY | 668.54 Million INR | 55.66% |
| 2010 FY | 429.5 Million INR | 10.74% |
| 2009 FY | 387.83 Million INR | 23.69% |
| 2008 FY | 313.56 Million INR | 20.22% |
| 2007 FY | 260.81 Million INR | -1.77% |
| 2006 FY | 265.51 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 92.643% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 97.024% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 89.971% |
| Granules India Limited | 7.18 Billion INR | 83.745% |
| Indoco Remedies Limited | 4.74 Billion INR | 75.415% |
| Achyut Healthcare Limited | 1.6 Million INR | -72459.291% |
| Ajanta Pharma Limited | 30.46 Billion INR | 96.168% |
| Alkem Laboratories Limited | 32.83 Billion INR | 96.444% |
| Alpa Laboratories Limited | 156.14 Million INR | -647.679% |
| Brooks Laboratories Limited | 51.18 Million INR | -2181.123% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 55.104% |
| Bajaj HealthCare Limited | 985.34 Million INR | -18.484% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 17.738% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.782% |
| Eris Lifesciences Limited | 4.94 Billion INR | 76.381% |
| FDC Limited | 5.34 Billion INR | 78.172% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.272% |
| Gufic Biosciences Limited | 1.07 Billion INR | -8.33% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 45.039% |
| Ipca Laboratories Limited | 13.91 Billion INR | 91.61% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -50.952% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2429.42% |
| Lasa Supergenerics Limited | 291.17 Million INR | -300.956% |
| Laurus Labs Limited | 3.01 Billion INR | 61.224% |
| Lupin Limited | 95.67 Billion INR | 98.78% |
| Mankind Pharma Limited | 23.15 Billion INR | 94.957% |
| Medicamen Biotech Limited | 335.16 Million INR | -248.328% |
| Medico Remedies Limited | 161.84 Million INR | -621.361% |
| Megasoft Limited | 49.52 Million INR | -2257.21% |
| NATCO Pharma Limited | 10.05 Billion INR | 88.393% |
| Piramal Pharma Limited | 19.91 Billion INR | 94.137% |
| RPG Life Sciences Limited | 1.63 Billion INR | 28.616% |
| Sigachi Industries Limited | 579.88 Million INR | -101.329% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.243% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 16.774% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -23.884% |
| Unichem Laboratories Limited | 6.72 Billion INR | 82.642% |
| Wanbury Limited | 1.16 Billion INR | -0.564% |
| Windlas Biotech Limited | 1 Billion INR | -15.993% |
| ZIM Laboratories Limited | 1.01 Billion INR | -15.243% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 97.296% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 62.055% |
| Divi's Laboratories Limited | 14.17 Billion INR | 91.761% |
| Hester Biosciences Limited | 908.84 Million INR | -28.458% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 61.024% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -6.232% |
| Bal Pharma Limited | 389.89 Million INR | -199.438% |
| Strides Pharma Science Limited | 9.16 Billion INR | 87.258% |
| Venus Remedies Limited | 1.91 Billion INR | 39.076% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 62.026% |
| Nectar Lifesciences Limited | 625.55 Million INR | -86.632% |
| Shilpa Medicare Limited | 2.18 Billion INR | 46.46% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -6.25% |
| Suven Life Sciences Limited | 109.75 Million INR | -963.762% |
| Ind-Swift Limited | 946.56 Million INR | -23.338% |
| Valiant Laboratories Limited | 36.28 Million INR | -3117.17% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 86.13% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 74.508% |
| Themis Medicare Limited | 782.85 Million INR | -49.131% |
| Hikal Limited | 2.48 Billion INR | 53.044% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.55% |
| Sequent Scientific Limited | 2.9 Billion INR | 59.767% |
| Novartis India Limited | 470.1 Million INR | -148.347% |
| Wockhardt Limited | 6.4 Billion INR | 81.758% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 91.923% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -7102.348% |
| Neuland Laboratories Limited | 2.92 Billion INR | 60.151% |
| Morepen Laboratories Limited | 1.98 Billion INR | 41.257% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -183.075% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -72.666% |